Analytical Data
-
基因名
FUCA1
- Application
-
别名
A-FU; aFU; Alpha-L-Fucosidase; Alpha-L-fucoside fucohydrolase 1
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P04066
-
表达区间
Phe53~Pro289
-
分子量
32kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FUCA1 (fucosidase alpha L-fucosidase) is an essential enzyme involved in the metabolism of fucose, a hexose deoxy sugar that plays a critical role in various biological processes, including cell signaling, immune response, and pathogen recognition. Mutations in the FUCA1 gene are associated with fucosidosis, a rare lysosomal storage disorder characterized by neurological deficits and skeletal anomalies. The study of FUCA1 recombinant protein serves multiple purposes: it aids in understanding enzyme structure-function relationships, facilitates investigations into the metabolic pathways involving fucose, and supports the development of potential therapeutic strategies for fucosidosis. By producing FUCA1 in a recombinant system, researchers can obtain large quantities of the enzyme, allowing for detailed biochemical characterization, crystallization studies, and the assessment of its activity under various conditions. Furthermore, this approach enables the generation of specific antibodies and inhibitors that can be utilized in diagnostic applications or as potential treatments. The exploration of FUCA1 not only enhances our comprehension of fucose metabolism but also opens avenues for therapeutic interventions targeting related disorders, thereby contributing to the broader field of glycobiology and personalized medicine.












